Literature DB >> 2736355

Long-term follow-up after choledochojejunostomy for bile duct stones with complex clearance of the bile duct.

D J Gouma1, J Konsten, P B Soeters, M Von Meyenfeldt, H Obertop.   

Abstract

In this retrospective study, the long-term follow-up of patients undergoing choledochojejunostomy (Roux-en-Y) for bile duct stones with complex clearance of the bile duct is evaluated. Bile duct exploration and subsequent choledochojejunostomy (Roux-en-Y) was performed in 43 patients (median age 67 years) in the period 1976-82. There was no mortality and only one patient had a major complication. Twenty patients died during follow-up (median follow-up period 5 years); the median follow-up period for the remaining 23 patients was 8 years. Good long-term results were found in 98 per cent of cases. No signs or symptoms could be related to bile duct obstruction or to cholangitis. Nearly all liver function tests and serum bilirubin levels were normal in the 21 patients who were tested. We conclude that patients with bile duct stones with complex clearance of the bile duct can be safely treated by means of a choledochoenterostomy (in this study a choledochojejunostomy Roux-en-Y).

Entities:  

Mesh:

Year:  1989        PMID: 2736355     DOI: 10.1002/bjs.1800760509

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Biliary strictures complicating pancreaticoduodenectomy.

Authors:  B J Ammori; S Joseph; M Attia; J P Lodge
Journal:  Int J Pancreatol       Date:  2000-08

Review 2.  Regeneration of extrahepatic bile ducts by tissue engineering with a bioabsorbable polymer.

Authors:  Mitsuo Miyazawa; Masayasu Aikawa; Katsuya Okada; Yasuko Toshimitsu; Kojun Okamoto; Isamu Koyama; Yoshito Ikada
Journal:  J Artif Organs       Date:  2011-07-23       Impact factor: 1.731

3.  Evaluation of biliary enteric anastomosis in benign biliary disorders.

Authors:  Devinder Pal Singh; Sohrab Arora
Journal:  Indian J Surg       Date:  2012-07-13       Impact factor: 0.656

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.